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Nephrotic syndrome, after administration of tyrosine kinase inhibitors, is uncommon and not well known. A 62-year-old male,
who had experienced a left nephrectomy due to a traﬃc accident 38 years ago, underwent a partial nephrectomy for right renal
cell carcinoma (RCC). Histologically, the tumor was a clear cell RCC. Two years later abdominal CT revealed para-aortic lymph
node metastasis. During these two years, serum creatinine had increased from 2.0mg/dL to 2.9mg/dL along with the appearance
of proteinuria. After only a week of sorafenib, 400mg/day, fever developed and sorafenib was stopped. Although normotensive,
his serum creatinine increased to 3.83mg/dL and serum albumin decreased from 1.8g/L to 1.0g/L. Proteinuria also worsened to
27.5g/day. He became edematous, and ascites and cardiac eﬀusions also appeared. He was diagnosed with nephrotic syndrome. A
retrospective review of the histology of the partial nephrectomy revealed no change in the glomeruli.
1.Introduction
Recently,vascularendothelialgrowthfactor(VEGF)receptor
blockers have been commonly used for treating advanced
renal cell carcinoma (RCC). Although renal dysfunction
caused by these inhibitors is uncommon, it is important for
advanced RCC because many RCC cases have chronic kidney
disease [1, 2]. However, this uncommon adverse eﬀect has
not been well documented.
2.CaseReport
A 62-year-old male, who had been subjected to a left neph-
rectomy due to a traﬃc accident at the age of 24, was admit-
ted for treatment of a right renal cell carcinoma, which mea-
sured11cmindiameter.Partialnephrectomywasperformed
that included 25 minutes of warm ischemic time. Histo-
logically, the tumor was a clear cell RCC without perinephric
fat or microvascular invasions.
Two years after the surgery, abdominal CT revealed para-
aortic lymph node metastasis, 2.5cm in diameter, which was
conﬁrmed histologically by CT-guided biopsy. During the
twoyearsafterthepartialnephrectomy,serumcreatininehad
increased gradually from 2.0mg/dL to 2.9mg/dL together
with the appearance of proteinuria.
Sorafenib, 400mg/day, was started but after only a week
of administration a fever developed and sorafenib was
stopped. Although he was normotensive after the cessation
of sorafenib, serum creatinine increased to 3.83mg/dL and
serumalbumin decreasedfrom1.8g/Lto 1.0g/L.Proteinuria
also worsened; the amount of urinary protein was 27.5g/day.
He became edematous and his body weight increased from
53.5kg to 57.6kg. Ascites and cardiac eﬀusions also ap-
peared.
He was diagnosed with nephrotic syndrome. With sodi-
um restriction, supplementation of albumin, and adminis-
tration of diuretics, his edema, ascites, and cardiac eﬀusions
were improved. The amount of urinary protein was also re-
duced to 9.4g/day.
Renal biopsy was not performed because of the possible
complications that could progress to deterioration of renal
function. A retrospective review of the histology of the2 Case Reports in Medicine
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Figure 1
partial nephrectomy revealed no change in the glomeruli
(Figure 1).
3. Discussion
Ablation of the kidney results in proteinuria, hypertension,
progressive renal failure, and advanced glomerulosclerosis
in animal models [1]. Also, clinically in chronic kidney
disease,glomerularﬁltrationrateunder60mL/minisknown
to develop within three years in two thirds of cases that
underwent radical nephrectomy [2]. As this case involved
a partial nephrectomy for RCC in a solitary kidney, only a
small volume of parenchyma remained, which could cause
progression of renal dysfunction after the surgery.
Nephrotic syndrome induced by tyrosine kinase in-
hibitors (TKIs) such as sorafenib and sunitinib has been
reported only in several cases [3–9], although it seems more
common in cases treated by bevacizumab, a humanized
monoclonal antibody neutralizing VEGF. However, the
etiology is not fully understood [10]. VEGF, produced by
podocytes,activatesVEGFreceptor2onglomerularcapillary
endothelialcells.Itsinhibitionmaycausealossofendothelial
fenestrations and reduced proliferation of endothelial cells.
Thrombotic microangiopathy and hypertension induced by
anti-VEGF therapy may play a role [10].
Before administration of sorafenib, this case was already
in renal insuﬃciency with low serum albumin and pro-
teinuria, although it did not meet the diagnostic criteria
of nephrotic syndrome. However, cases without proteinuria
have been reported to develop nephrotic syndrome after
TKI treatment [3–7]. Although the risk factors for renal
dysfunction after anti-VEGF therapy remain unknown, this
infrequent adverse eﬀect cannot be ignored.
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